The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease

Bibliography

• Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD). 2015; Available from: www.goldcopd.org/ [ Last accessed 9 August 2015]
   Google Scholar
• Rosenberg SR, Kalhan R, Mannino DM. Epidemiology of COPD: Prevalence, Morbidity, Mortality, and Risk Factors. Semin Respir Crit Care Med 2015;36:457-69
   PubMed Web of Science ®Google Scholar
• Kochanek KD, et al. Deaths: Preliminary data for 2009. Nat Vital Stat Reports 2011;59:1-51
   Google Scholar
• American Thoracic Society, European Respiratory Society. Standards for the Diagnosis and Management of Patients with COPD. Available from: www.thoracic.org/clinical/copd-guidelines/resources/copddoc.pdf [ Last accessed 9 August 2015]
   Google Scholar
• Tashkin DP, Celli B, Senn S, for the UPLIFT study investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54
   PubMed Web of Science ®Google Scholar
• Donohue JF. Therapeutic responses in asthma and COPD. Bronchodilators. Chest 2004;126(2 Suppl):125S-37S
   PubMedGoogle Scholar
• Calverley PMA, Burge PS, Spencer S, for the ISOLDE Study Investigators. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-64
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24
   PubMed Web of Science ®Google Scholar
• Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012;40:830-6
   PubMed Web of Science ®Google Scholar
• Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 µg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012;141:745-52
   PubMed Web of Science ®Google Scholar
• D’Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011;12:156
   PubMed Web of Science ®Google Scholar
• Kerwin E, Hebert J, Gallaher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012;40:1106-14
   PubMed Web of Science ®Google Scholar
• Carter NJ. Inhaled glycopyrronium bromide: A review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs 2013;73:741-53
   PubMed Web of Science ®Google Scholar
• Donohue JF, Anzueto A, Brooks J, et al. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012;106:970-9
   PubMed Web of Science ®Google Scholar
• Trivedi R, Richard N, Mehta R, et al. Umeclidinium in patients with chronic obstructive pulmonary disease: a randomized, placebo-controlled study. Eur Respir J 2014;43:72-81
   PubMed Web of Science ®Google Scholar
• Decramer M, Maltais F, Geldman G, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013;185:393-9
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord JA, Greefhorst SPM, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002;19:209-16
   PubMed Web of Science ®Google Scholar
• Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 hr with once-daily tiotropium in patients with COPD. Chest 2005;128:1168-78
   PubMed Web of Science ®Google Scholar
• Verkindre C, Bart F, Aguilaniu et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006;73:420-7
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40
   PubMed Web of Science ®Google Scholar
• Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143(5):317-26
   PubMed Web of Science ®Google Scholar
• Mahler DA, Kerwin E, Ayers T, et al. FLIGHT: Efficacy and safety of QVA 149 (indacaterol/glycopyrrolate) versus ints monocomponents and placebo in patients with COPD. Am J Respir Crit Care Med 2015. [Epub ahead of print]
   Google Scholar
• Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014;15:78
   PubMed Web of Science ®Google Scholar
• Blair HA, Deeks ED. Umeclidinium/vilanterol: A review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs 2015;75:61-74
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H. A systematic review on the efficacy and safety of a fixed-dose combination of umeclidinium and vilaterol for the treatment of COPD. Chest 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med 2014;108:1752-60
   PubMed Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015;45:969-79
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993;52:521-7
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004;117(Suppl 1):24-32
   Google Scholar
• Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol 2008;154:1558-71
   PubMed Web of Science ®Google Scholar
• Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-64
   PubMed Web of Science ®Google Scholar
• Pappano AJ. Cholinoceptor blocking drugs. In: Karzung BG, Trevor AJ, editors. Basic and Clinical Pharmacology. 13th edition. McGraw-Hill Education Companies, Inc., New York; 2015; p. 121-32
   Google Scholar
• Putcha N, Drummond MB, Wise RA. Comorbidities and COPD: Prevalence, influence on outcomes and management. Semin Respir Crit Care Med 2015;36:575-91
   PubMed Web of Science ®Google Scholar
• Lofdahl C-G. COPD and co-morbidities, with special emphasis on cardiovascular conditions. Clin Respire J 2008;2:59-63
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline in FEV1: The Lung Health Study. JAMA 1994;272:1497-505
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-9
   PubMed Web of Science ®Google Scholar
• Sin DD, Tu JV. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive pulmonary disease. Thorax 2000;55:194-7
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 2008;300:1439-50
   PubMed Web of Science ®Google Scholar
• Macie C, Wooldrage K, Manfreda J, et al. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J COPD 2008;3:163-9
   Google Scholar
• Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;1498:380-9
   Google Scholar
• Lanes S, Golisch W, Miki J. Ipratropium and lung health study. Am J Respir Crit Care Med 2003;167P:801-2
   Google Scholar
• Zierenberg B. Optimizing the in vitro performance of Respimat®. J Aerosol Med 1999;12(Suppl 1):S19-24
   PubMedGoogle Scholar
• Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 mcg via Respimate and 18 mcg via Handihaler efficacy and safety in Japanese COPD patients. Respir Med 2010;104:228-36
   PubMed Web of Science ®Google Scholar
• Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369:1491-501
   PubMed Web of Science ®Google Scholar
• Kesten S, Wentworth JM, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-703
   PubMed Web of Science ®Google Scholar
• Kesten S, Celli B, Decramer M, et al. Tiotropium Handihaler in the treatment of COPD: A safety review. Int J COPD 2009;4:397-409
   Google Scholar
• Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Therap 2007;20:495-502
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Casro-Rodriguez JA, Nannini LJ, et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: Systematic review with meta-analysis. Respir Med 2009;103:1421-9
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30
   PubMed Web of Science ®Google Scholar
• Halpin D, Dahl R, Hallmann C, et al. Tiotropium HandiHaler® and Respimat® in COPD: a pooled analysis. Int J COPD 2015;10:239-5
   Google Scholar
• Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: The Uplift Trial. COPD: Journal of Chronic Obstructive Pulmonary Disease 2004;1:303-12
   Google Scholar
• Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:948-55
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Decramer M, Leimer I, et al. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT trial. Respir Res 2015;16:65
   PubMed Web of Science ®Google Scholar
• Afonso ASM, Verhammer KMC, Stricker BHC, et al. Inhaled anticholinergic drugs and risk of acute urinary retention. BJUI 2010;107:265-72
   Google Scholar
• Stephenson A, Seitz D, Bell CM, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease. Arch Intern Med 2011;171:914-20
   PubMed Web of Science ®Google Scholar
• Vande Griend JP, Linnebur SA. Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia. Ann Pharmacother 2012;46:1245-9
   PubMed Web of Science ®Google Scholar
• Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854-62
   PubMed Web of Science ®Google Scholar
• Walker S, Fingleton J, Weatherall M, Beasley R. Limited generalisability of UPLIFT findings to clinical practice. Thorax 2013;68:1066-7
   PubMed Web of Science ®Google Scholar
• De Luise C, Lanes SF, Jacobsen J, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007;22:267-72
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Metzdorf N, Hallmann C, et al. Safety of tiotropium in renally impaired patients. (Abstract). Presented at the European Respiratory Society Annual Congress. Munich, Germany, September 2014
   Google Scholar
• Hochrainer D, Holz H, Kreher C, et al. Comparison if the aerosol velocity and spray duration of Respimat® Soft Mist™ Inhaler and pressurized metered dose inhalers. J Aerosol Med 2005;18:273-82
   PubMedGoogle Scholar
• Caillard D, Le Merre C, Maartinat Y, et al. A dose-ranging study of tiotropium delivered via Respimat® Soft Mist™ Inhaler or Handihaler® in COPD patients. Int J COPD 2007;2:559-65
   Google Scholar
• Van Noord JA, Cornelissen PJ, Aumann LK, et al. The efficacy of tiotropium administed via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009;103:22-9
   PubMed Web of Science ®Google Scholar
• Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J COPD 2010;5:197-208
   Google Scholar
• Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med 2010;104:1460-72
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Tiotropium (Spiriva) Respimat: evaluation of fatal events. 2010; Available from: http://trials.Boehringer-ingelheim.com/content/dam/internet/opu/clinicalgtrial/com_EN/results/Pooled%20analysis/PA_205.372_251_252_254_255_U10-3255-01.pdf
   Google Scholar
• Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systemataic review and meta-analysis of randomized controlled trials. BMJ 2011;14:342-d3215
   Google Scholar
• Verhamme KM, Afonso A, Romio S, et al. Use of tiotropium Respimat SMI vs. tiotropium Handihaler and mortality in patients with COPD. Eur Respir J 2013;42:605-15
   Web of Science ®Google Scholar
• Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomized controlled trials. Thorax 2013;68:48-56
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S. Risks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to date. Ther Adv Drug Safe 2012;3:123-31
   Google Scholar
• Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD009285
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Seebri Breezhaler (glycopyrronium bromide): European Medicines Agency assessment report. 1012. Available from: www.ema.europa.eu/docs/en_GB/docment_library/EPAR_-_Public_assessment_report/human/002430/WC500133771.pdf
   Google Scholar
• D’Urzo AD, Kerwin E, Chapman KR, et al. Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data. Int J COPD 2015;10:1599-612
   Google Scholar
• Prat M, Fernandez D, Buil MA, et al. Discovery of novel quaternary ammonium derivatives of the (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-[huydroxy(di-2-thienyl) acetyl]oxy-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octance bromide (aclidiinium bromide). J Med Chem 2009;52:5076-92
   PubMed Web of Science ®Google Scholar
• Gavalda A, Miralpeix M, Ramos I, et al. Characterizatioin of aclidiniium bromide, a novel inhaled muscarinic antagonist with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009;331:740-51
   PubMed Web of Science ®Google Scholar
• Jansat JM, Lamarca R, de Miquel G, et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease in healthy participants. J Clin Pharmacol 2009;49:1239-46
   PubMed Web of Science ®Google Scholar
• Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidiniuim in chronic obstructive pulmonary disease. Respir Res 2011;12:55
   PubMed Web of Science ®Google Scholar
• Gelb AF, Tashkin DP, Make BJ, et al. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respir Med 2013;107:1957-65
   PubMed Web of Science ®Google Scholar
• Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One 2012;7:1-9
   Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;1-7:1538-46
   Web of Science ®Google Scholar
• Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol in patients with chronic obstructive pulmonary disease: results from two multicentgre, blinded, randomized controlled trials. Lancet Respir Med 2014;2:472-86
   PubMed Web of Science ®Google Scholar
• Naccarelli G, Finkle J, Chopra B, et al. Cardiovascular safety of umeclidinium/vilanterol in COPD: results from eight randomized clinical trials (abstract no. A3766). Presented at The 110th International Conference of the American Thoracic Society San Diego, 2014
   Google Scholar
• FDA. Follow-up to the October 2008 updated early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). January 14, 2010
   Google Scholar
• Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev 2014;26(3):CD010844
   Google Scholar
• Cazzola M, Matera MG, Donner CF. Inhaled beta-2 adrenoceptor agonists, cardiovascular safety in patients with obstructive lung disease. Drugs 2005;65:1595-610
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD. Chest 2004;125:2309-21
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: Anticholinergic, but not b-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006;21:1011-19
   PubMed Web of Science ®Google Scholar
• Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993;3:335-48
   PubMed Web of Science ®Google Scholar
• Kerwin EM, D’Urzo AD, Gelb AR, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012;9:90-101
   PubMedGoogle Scholar